等待开盘 09-18 09:30:00 美东时间
+1.210
+8.97%
Biohaven核心驱动因素在于主要资产曲鲁唑(troriluzole)有望潜在获得FDA批准,花旗银行给予该股买入评级并设定每股28美元目标价。
今天 14:22
今日重点评级关注:HC Wainwright & Co.:维持Astria Therapeutics"买入"评级,目标价从16美元升至20美元;HC Wainwright & Co.:维持Avalo Therapeutics"买入"评级,目标价从15美元升至25美元
今天 10:13
今日重点评级关注:HC Wainwright & Co.:维持Orion Energy Sys"买入"评级,目标价从2美元升至20美元;高盛:维持Amylyx Pharmaceuticals"买入"评级,目标价从10美元升至20美元
09-17 10:15
UBS analyst Ashwani Verma maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $27 to $26.
09-16 20:43
As HHS Secretary Robert F. Kennedy Jr. continues to fend off criticism of his leadership and decisions at the agency, if he were to leave the post, Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA)...
09-11 03:54
今日重点评级关注:花旗:维持Ionis Pharmaceuticals"买入"评级,目标价从69美元升至84美元;Melius Research:上调康明斯评级至"买入",目标价500美元
09-04 09:49
Raymond James analyst Chris Raymond initiates coverage on Biohaven (NYSE:BHVN) with a Strong Buy rating and announces Price Target of $75.
09-04 00:44
Aclass actionlawsuit was filed againstBiohaven Ltd. ($BHVN) b...
08-28 17:55
此前,美国FDA取消了原计划就Biohaven核心药物troriluzole上市申请召开的咨询委员会(AdCom)会议,该股盘前飙涨。
08-22 20:31
Gainers ModivCare (NASDAQ:MODV) stock increased by 69.6% to $0.95 during Frida...
08-22 20:08